Advances in Geriatrics / 2014 / Article / Tab 3 / Review Article
CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design Table 3 Proposed NIA-AA criteria for the diagnoses of Alzheimer’s disease (AD), mild cognitive impairment due to AD, and preclinical AD.
Criteria Biomarkers Cognition Diagnosis Likelihood of AD Alzheimer’s disease
1 Original-clinical aloneN/A AD dementia or non-AD dementia N/A Amyloid Injury Cognition
2 Revised-clinical + biomarkers*+ ? AD dementia Probable AD dementia Intermediate ? + AD dementia Probable AD dementia Intermediate + + AD dementia Probable AD dementia Highest + + Non-AD dementia Possible AD dementia (with atypical presentation) High (but does not rule out second etiology) − − Non-AD dementia Dementia (unlikely due to AD) Lowest Mild cognitive impairment
3 Original-clinical aloneN/A MCI N/A Amyloid Injury Cognition
4 Revised-clinical + biomarkers*+ ? MCI MCI due to AD Intermediate ? + MCI MCI due to AD Intermediate + + MCI MCI due to AD Highest − − MCI MCI due to AD Lowest Preclinical Alzheimer’s disease
5 Original-clinical alone N/A N/A N/A Amyloid Injury Cognition Subtle cognitive decline
6 Revised-clinical + biomarkers**− − No dementia −
7 Stage 0/normalN/A + − No dementia − Stage 1 : asymptomatic cerebral amyloidosisN/A + + No dementia − Stage 2 : asymptomatic cerebral amyloidosis + neurodegenerationN/A + + No dementia + Stage 3 : asymptomatic cerebral amyloidosis + neurodegeneration + subtle cognitive/behavioral declineN/A − + No dementia +/−
7 SNAP (suspected non-AD pathophysiology)N/A
McKhann et al., 1984 [7 ].
2 McKhann et al., 2011 [14 ].
3 Petersen et al., 1999 [62 ]; Petersen 2004 [63 ].
4 Albert et al., 2011 [15 ].
5 Not recognized as a classification.
6 Sperling et al., 2011 [16 ].
7 Jack et al., 2012 [74 ].
*Proposed for clinical and research use.
**Proposed for research use only.